146 related articles for article (PubMed ID: 30557902)
1. Apolipoprotein CIII and diabetes. Is there a link?
Christopoulou E; Tsimihodimos V; Filippatos T; Elisaf M
Diabetes Metab Res Rev; 2019 Mar; 35(3):e3118. PubMed ID: 30557902
[TBL] [Abstract][Full Text] [Related]
2. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
Rocha NA; East C; Zhang J; McCullough PA
Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
[TBL] [Abstract][Full Text] [Related]
3. Recent Apolipoprotein CIII trials.
Tramontano D; Bini S; D'Erasmo L; Arca M
Curr Opin Lipidol; 2022 Dec; 33(6):309-318. PubMed ID: 36206093
[TBL] [Abstract][Full Text] [Related]
4. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.
Ebara T; Ramakrishnan R; Steiner G; Shachter NS
J Clin Invest; 1997 Jun; 99(11):2672-81. PubMed ID: 9169497
[TBL] [Abstract][Full Text] [Related]
5. ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia.
Kypreos KE
Biochemistry; 2008 Sep; 47(39):10491-502. PubMed ID: 18767813
[TBL] [Abstract][Full Text] [Related]
6. Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease.
Zheng C
Curr Opin Lipidol; 2014 Feb; 25(1):35-9. PubMed ID: 24345989
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes.
Åvall K; Ali Y; Leibiger IB; Leibiger B; Moede T; Paschen M; Dicker A; Daré E; Köhler M; Ilegems E; Abdulreda MH; Graham M; Crooke RM; Tay VS; Refai E; Nilsson SK; Jacob S; Selander L; Berggren PO; Juntti-Berggren L
Proc Natl Acad Sci U S A; 2015 May; 112(20):E2611-9. PubMed ID: 25941406
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein CIII is a new player in diabetes.
Juntti-Berggren L; Berggren PO
Curr Opin Lipidol; 2017 Feb; 28(1):27-31. PubMed ID: 27875339
[TBL] [Abstract][Full Text] [Related]
9. Increased inflammation, endoplasmic reticulum stress and oxidative stress in endothelial and macrophage cells exacerbate atherosclerosis in ApoCIII transgenic mice.
Yingchun H; Yahong M; Jiangping W; Xiaokui H; Xiaohong Z
Lipids Health Dis; 2018 Sep; 17(1):220. PubMed ID: 30223835
[TBL] [Abstract][Full Text] [Related]
10. Role of apolipoprotein CIII in triglyceride-rich lipoprotein metabolism.
Fredenrich A
Diabetes Metab; 1998 Dec; 24(6):490-5. PubMed ID: 9932215
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein CIII may mediate the impacts of angiopoietin-like protein 8 on triglyceride metabolism.
Luo M; Su X; Yi Y; Yang Y; Peng D
Lipids Health Dis; 2018 Jul; 17(1):160. PubMed ID: 30021607
[TBL] [Abstract][Full Text] [Related]
12. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia.
Morton AM; Furtado JD; Lee J; Amerine W; Davidson MH; Sacks FM
J Clin Lipidol; 2016; 10(6):1442-1451.e4. PubMed ID: 27919362
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.
Aalto-Setälä K; Fisher EA; Chen X; Chajek-Shaul T; Hayek T; Zechner R; Walsh A; Ramakrishnan R; Ginsberg HN; Breslow JL
J Clin Invest; 1992 Nov; 90(5):1889-900. PubMed ID: 1430212
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein CIII links dyslipidemia with atherosclerosis.
Kawakami A; Yoshida M
J Atheroscler Thromb; 2009 Mar; 16(1):6-11. PubMed ID: 19262004
[TBL] [Abstract][Full Text] [Related]
15. Hypertriglyceridemia and delayed clearance of fat load in transgenic rabbits expressing human apolipoprotein CIII.
Ding Y; Wang Y; Zhu H; Fan J; Yu L; Liu G; Liu E
Transgenic Res; 2011 Aug; 20(4):867-75. PubMed ID: 21120692
[TBL] [Abstract][Full Text] [Related]
16. Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII.
Li H; Han Y; Qi R; Wang Y; Zhang X; Yu M; Tang Y; Wang M; Shu YN; Huang W; Liu X; Rodrigues B; Han M; Liu G
Cardiovasc Res; 2015 Sep; 107(4):579-89. PubMed ID: 26160324
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia.
Caron S; Verrijken A; Mertens I; Samanez CH; Mautino G; Haas JT; Duran-Sandoval D; Prawitt J; Francque S; Vallez E; Muhr-Tailleux A; Berard I; Kuipers F; Kuivenhoven JA; Biddinger SB; Taskinen MR; Van Gaal L; Staels B
Arterioscler Thromb Vasc Biol; 2011 Mar; 31(3):513-9. PubMed ID: 21183731
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells.
Kawakami A; Aikawa M; Libby P; Alcaide P; Luscinskas FW; Sacks FM
Circulation; 2006 Feb; 113(5):691-700. PubMed ID: 16461842
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits.
Yan H; Niimi M; Matsuhisa F; Zhou H; Kitajima S; Chen Y; Wang C; Yang X; Yao J; Yang D; Zhang J; Murakami M; Nakajima K; Wang Y; Liu E; Liang J; Chen YE; Fan J
Arterioscler Thromb Vasc Biol; 2020 Sep; 40(9):2095-2107. PubMed ID: 32757647
[TBL] [Abstract][Full Text] [Related]
20. Dietary fructose and dyslipidemia: new mechanisms involving apolipoprotein CIII.
Hieronimus B; Stanhope KL
Curr Opin Lipidol; 2020 Feb; 31(1):20-26. PubMed ID: 31789670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
